Loading
A phase 3 trial of VT3989 run by Vivace Therapeutics, Inc, not yet recruiting.
A Phase 3 Trial in Advanced Epithelioid Mesothelioma is a phase 3 interventional study registered as NCT07824986 by Vivace Therapeutics, Inc, with 350 participants planned, started 2026-12-01, primary completion expected 2028-05-01. Conditions recorded: Pleural Mesothelioma, Mesothelioma. Interventions recorded: VT3989, gemcitabine, Vinorelbine.
Shares Pleural mesothelioma, Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares VT3989, Vivace Therapeutics, Mesothelioma.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/